Dehydroepiandrosterone and diseases of aging

Drugs and Aging

Volumn 9, Issue 4, 1996, Pages 274-291

  Watson, Ronald R ^a   Huls, Adele ^a   Araghinikuam, Moshen ^a   Chung, Sangbun ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLANT EXTRACT; PRASTERONE; VITAMIN;

AGED; AGING; ATHEROSCLEROSIS; CANCER; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG SAFETY; FEMALE; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HORMONE SYNTHESIS; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RAT; REVIEW; SMOKING;

EID: 0029959711     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609040-00005     Document Type: Review

References (141)

1. Del Ponte A, Di Monte MG, Graziani D, et al. Changes in plasma DHEAS circadian rhythm in elderly men. Prog Clin Biol Res 1990; 341: 791-6
2. Littley MD, Pollock A, Kane J, et al. Basal serum dehydroepiandrosterone sulfate concentration does not predict the cortisol response to provocative testing. Ann Clin Biochem 1990; 27: 557-61
3. Maki T. Age-related changes in secretion of adrenocortical steroid hormones in normal healthy men. Nippon Naibunpi Gakkai Zasshi 1986; 62: 672-82
4. Pavlov EP, Harman SM, Chrousos GP, et al. Responses of plasma adrenocorticotropin, cortisol, and dehydroepiandrosterone (DHEA) to ovine corticotropin-releasing hormone in healthy aging men. J Clin Endocrinol Metab 1986; 62: 767-72
5. Orentreich N, Brind JL, Rizer RL, et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59: 551-5
6. Birkenhager-Gillesse EG, Derksen J, Lagaay AM. Dehydroepiandrosterone sulfate (DHEAS) in the oldest old, aged 85 and over. Ann N Y Acad Sci 1994; 719: 543-52
7. Salvini S, Stampfer MJ, Barbieri RL, et al. Effects of age, smoking and vitamins on plasma DHEAS levels: a cross-sectional study in men. J Clin Endocrinol Metab 1992; 74: 139-43
8. National Institutes of Health (NIH). Consensus development conference on osteoporosis. NIH Consensus Development Conference Statement 1984, 5(3). Washington. DC: US Government Printing Office, 1984: 4652 [DHHS(PHS) 421-132]
9. Murphy S, Khaw KT, Cassidy A, et al. Sex hormones and bone mineral density in elderly men. Bone Miner 1993; 20: 133-40
10. Rozenberg S, Ham H, Bosson D. Age, steroids and bone mineral content. Maturitas 1990; 12: 137-43
11. Taelman P, Kaufman JM, Janssens X, et al. Persistence of increased bone resorption and possible role of dehydroepiandrosterone as a bone metabolism determinant in osteoporotic women in late post-menopause. Maturitas 1989; 11: 65-73
12. Wild RA, Buchanan JR, Myers C, et al. Declining adrenal androgens: an association with bone loss in aging women. Proc Soc Exp Biol Med 1987; 186: 355-60
13. Lee JR. Natural progesterone. Sebastopol (CA): BLL Publishing, 1993: 56
14. Spector TD, Thompson PW, Perry LA, et al. The relationship between sex steroids and bone mineral content in women soon after menopause. Clin Endoerinol 1991; 34: 37-41
15. Szathmari M, Szucs J, Feher T, et al. Dehydroepiandrosterone sulfate and bone mineral density. Osteoporos Int 1994; 4: 84-8
16. Vermeulen A, Deslypere JP, Paridaens R. Steroid dynamics in the normal and pathologic mammary gland [abstract]. J Steroid Biochem 1985; 23 Suppl.: 8S
17. Buster JE, Casson PR, Straughn AB, et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. Am J Obstet Gynecol 1992; 166: 1163-70
18. Mortola JK, Yen SSC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in post-menopausal women. J Clin Endocrinol Metab 1990; 71: 696-704
19. Bronner F. Calcium and osteoporosis. Am J Clin Nutr 1994; 60: 831-6
20. Watson RR. Prevention of immune dysfunction by dehydroepiandrosterone in aging, chronic AIDS and leukaemia patients. Exp Opin Invest Drugs 1995; 4: 147-54
21. Rao MS, Subbarao V, Yeldandi AV, et al. Inhibition of spontaneous testicular Leydig cell tumor development in F-344 rats by dehydroepiandrosterone. Cancer Lett 1992; 65: 123-6
22. Schwartz AG, Pashko LL. Cancer chemoprevention with the adrenocortical steroid dehydroepiandrosterone and structural analogs. J Cell Biochem Suppl 1993; 17G: 73-9
23. Schwartz AG, Pashko LL. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J Cellular Biochem 1995; 22 Suppl.: 210-7
24. Ratko TA, Detrisac CJ, Mehta RG, et al. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone. Cancer Res 1991; 51: 481-6
25. Garcea R, Daino L, Pascale R, et al. Inhibition by dehydroepiandrosterone of liver preneoplastic foci formation in rats alter initiation-selection in experimental carcinogenesis. Toxicol Pathol 1987; 15: 164-9
26. Klamm RC, Holbrooke CT, Nyce JW. Chemotherapy of murine colorectal carcinoma with cisplatin plus 3′-deoxy′3′-azidothymidine. Anticancer Res 1992; 12: 781-7
27. Labrie F, Dupont A, Simard J, et al. Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol 1993; 24 Suppl. 2: 94-105
28. Helzlsouer KJ, Gordon GB, Alberg AJ, et al. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992; 52: 1-4
29. Barrett-Connor E, Friedlander NJ, Khaw KT. Dehydroepiandrosterone sulfate and breast cancer risk. Cancer Res 1990; 50: 6571-4
30. Gordon GB, Bush TL, Helzlsouer RJ, et al. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res 1990; 50: 3859-62
31. Kawai S, Yahata N, Nishida S, et al. Dehydroepiandrosterone inhibits B16 mouse melanoma cell growth by induction of differentiation. Anticancer Res 1995; 15: 427-31
32. Ivanovic S, Agbaba D, Zivanov-Stakic D, et al. The urinary dehydroepiandrosterone, androsterone and etiocholanolone excretion of healthy women and women with benign and malignant breast disease. J Clin Pharm Ther 1990; 15: 213-9
33. Liberato MH, Sonohara S, Brentant MM. Effects of androgens on proliferation and progesterone receptor levels in T47D human breast cancer cells. Tumour Biol 1993; 14: 38-45
34. Boccuzzi G, Brignardello E, DiMonaco M, et al. Influence of dehydroepiandrosterone and 5-en-androstene-3 beta, 17 beta-diol on the growth of MCF-7 human breast cancer cells induced by 17 beta-estradiol. Anticancer Res 1992; 12: 799-803
35. Boccuzzi G, DiMonaco M, Brignardello E, et al. Dehydroepiandrosterone antiestrogenic action through androgen receptor in MCF-7 human breast cancer cell line. Anticancer Res 1993; 13: 2267-72
36. Lubet RA, McCormick DM, Gordon GM. et al. Effects of dehydroepiandrosterone on MNU-induced breast cancer in Sprague-Dawley rats. Ann N Y Acad Sci 1995; 774: 340-1
37. Gordon GB, Helzlsouer KJ, Alberg AJ, et al. Serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate and the risk of developing gastric cancer. Cancer Epidemiol Biomarkers Prev 1993; 2: 33-5
38. Bhalavdekar JM, Patel DD, Chikhikar RR, et al. Levels of circulating peptide and steroid hormones in men with lung cancer. Neoplasma 1994; 41: 101-3
39. Gordon GB, Helzlsouer KJ, Comstock GW. Serum levels of dehydroepiandrosterone and its sulfate and the risk of developing bladder cancer. Cancer Res 1991; 51: 1366-9
40. Magee JM, Mckenzie S, Filippa DA, et al. Hairy cell leukaemia: durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer 1985; 56: 2557-62
41. Hursting SD, Perkins SN, Haines DC, et al. Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res 1995; 55: 3949-53
42. Comstock GW, Gordon GB, Hsing AW. The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev 1993; 2: 219-21
43. Nyholm HV, Nielson AL, Lyndrup J, et al. Plasma oestrogens in post menopausal women with endometrial cancer. Br J Obstet Gynaecol 1993; 100: 1115-9
44. Rudman D, Shetty KR, Mattson DE. Plasma dehydroepiandrosterone sulfate in nursing home men. J Am Geriatr Soc 1990; 38: 421-7
45. Lane MA, Ingram DK, Roth GS. Effects of aging and long-term calorie restriction on DHEA and DHEA sulfate in Rhesus monkeys. Ann N Y Acad Sci 1995; 774: 319-22
46. Daynes RA, Araneo BA, Ershler WB, et al. Altered regulation of IL-6 production with normal aging: possible linkage to the age-associated decline in dehydroepiandrosterone and its sultated derivative. J Immunol 1993; 150: 5219-30
47. Alak JIB, Shahbazian M, Huang DS, et al. Alcohol and murine acquired immunodeficiency syndrome suppression of resistance to Cryptosporidium parvum infection during modulation of cytokine production. Alcohol Clin Exp Res 1993; 17: 539-44
48. Spencer NFL, Poynter ME, Hennebold JD, et al. Does DHEA restore immune competence in aged animals through its capacity to function as a natural modulator of peroxisome activities? Ann N Y Acad Sci 1995; 774: 200-16
49. Watson RR. Antioxidant restorers of immune defenses made dysfunctional by age or murine AIDS. Ross Conference Proceedings Nutritional Immunomodulation in Disease and Health Promotion. In press
50. Rasmussen KR, Martin EG, Healey MC. Effects of dehydroepiandrosterone in immunosuppressed rats infected with Cryptosporidium parvum. J Parasitol 1993; 79: 364-70
51. Rasmussen KR, Healey MC. Dehydroepiandrosterone-induced reduction of Cryptosporidium parvum infections in aged Syrian golden hamsters. J Parasitol 1992; 78: 554-7
52. Vasdev S, Johnson E, Longerich L, et al. Plasma endogenous digitalis-like factors in healthy individuals and in dialysis dependent and kidney transplant patients. Clin Nephrol 1987; 27: 169-74
53. Araneo BA, Shelby J, Li GZ, et al. Administration of DHEA to burned mice preserves normal immunologic competence. Arch Surg 1993; 128: 318-25
54. Araneo BA, Woods ML, Daynes RA. Reversal of the immunosenescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant effect on the immunization of aged mice with recombinant hepatitis B surface antigen. J Infect Dis 1993; 167: 830-40
55. Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, et al. Dehydroepiandroslerone enhances influenza immunization in aged mice. Ann N Y Acad Sci 1995; 774: 297-9
56. Loria RM, Padgett DA. Androstenediol regulates systemic resistance against lethal infections in mice. Arch Virol 1992; 127: 103-15
57. Wei J, Xu J, Davies JL, et al. Increase in plasma IL-6 concentration with age in healthy subjects. Life Sci 1992; 51: 1953-6
58. Daynes RA, Dudley DJ, Araneo BA. Regulation of murine lymphokine production in vivo: II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur J Immunol 1990; 20: 793-802
59. Hirano T, Kishimoto T. Interleukin-6. In: Spron MB, Roberts AB, editors. Peptide growth factors and their receptors. New York: Springer-Verlag, 1991: 633-65
60. Watson RR. DHEA and vitamin E: antioxidant restorers of immune defenses made dysfunctional by age or murine AIDS. Ross Conference Proceedings: Nutritional Immunomodulation in Disease and Health Promotion. In press
61. Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 1993; 169: 1536-9
62. Daynes RA, Araneo BA. Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4. Eur J Immunol 1990; 19: 2319-25
63. Daynes RA, Araneo BA, Dowel TA. Regulation of murine lymphokine production in vitro: III. The lymphoid microenvironment exerts regulatory influences over T helper function. J Exp Med 1990; 171: 979-96
64. Regelson W, Loria R, Kalimi M. Dehydroepiandrosterone (DHEA) - the 'mother steroid': I. Immunologic action. Ann N Y Acad Sci 1994; 719: 553-63
65. Araneo B, Daynes R. Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury. Endocrinology 1995; 136: 393-401
66. May M, Holmes E, Rogers W, et al. Protection from glucocorticoid-induced thymic involution by dehydroepiandrosterone. Life Sci 1990; 46: 1627-31
67. Goodyer IM, Herbert J, Altham PME, et al. Adrenal secretion during major depression in 8 to 16 year olds: altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation. Psychol Med 1996; 26: 245-56
68. Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women: potential remedial effects. Ann N Y Acad Sci 1995; 774: 128-42
69. Christeff N, Gharakhanian S, Thobie N, et al. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immune Defic Syndr 1992; 5: 841-6
70. Christeff N, Winter C, Gharakhanian S, et al. Differences in androgens of HIV positive patients with and without Kaposi sarcoma. J Clin Pathol 1995; 48: 513-8
71. Majewska MD. Neuronal actions of DHEAS: possible roles in brain development, aging, memory and affect. Ann N Y Acad Sci 1995; 774: 111-21
72. Flood JF, Morley JE, Robert E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci U S A 1992; 89: 1567-71
73. Flood JF, Roberts E. Dehydroepiandrosterone sulfate improves memory in aging mice. Brain Res 1988; 10: 178-81
74. Nasman B, Olsson T, Backstrom T, et al. Serum dehydroepiandrosterone sulfate in Alzheimer's disease and in multi-infarct dementia. Biol Psychiatry 1991; 30: 684-90
75. Dodt C, Dittman J, Hruby J, et al. Different regulation of adrenocorticotropin and cortisol secretion in young mentally healthy elderly and patients with senile dementia of Alzheimer's type. J Clin Endocrinol Metab 1991; 72: 272-6
76. Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360-7
77. Nestler JE, Clore JN, Blackard WG. The regulation of dehydroepiandrosterone metabolism by insulin and metabolic effects of dehydroepiandrosterone in man. In: Kalimi MY, Regelson W, editors. Dehydroepiandrosterone (DHEA). New York: Walter de Gruyer & Co., 1990: 189-205
78. Coleman DL. Dehydroepiandrosterone (DHEA) and diabetic syndromes in mice. In: Kalimi MY, Regelson W, editors. Dehydroepiandrosterone (DHEA). New York: Walter de Gruyer & Co., 1990: 179-88
79. Clearly MP. The antiobesity effect of dehydroepiandrosterone in rats. Soc Exp Biol 1990; 196: 8-16
80. Regelson W, Kalimi M. Dehydroepiandrosterone (DHEA) - the multifunctional steroid: II. Effects on the CNS, cell proliferation, metabolic and vascular, clinical and other effects. Mechanism of action? Ann N Y Acad Sci 1994; 719: 564-75
81. Nestler JE. Regulation of human dehydroepiandrosterone metabolism by insulin. Ann N Y Acad Sci 1995; 774: 73-81
82. Beer NA, Jakubowicz DJ, Beer RM, et al. The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum Cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 1993; 76: 1464-9
83. Mohan PF, Clearly MP. Comparison of dehydroepiandrosterone and clofibric acid treatments in obese zucker rats. J Nutr 1989; 119: 496-501
84. Clearly MP, Zabel T, Sartin JL. Effects of short-term dehydroepiandrosterone treatment on serum and pancreatic insulin in zucker rats. J Nutr 1988; 118: 382-7
85. Coleman DI, Schwizer RW, Leiter EH. Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice. Diabetes 1984; 33: 26-32
86. Coieman DI, Leiter EH, Schwizer RW. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 1982; 31: 830-3
87. Clearly MP, Zisk JF. Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female zucker rats. Int J Obes 1986; 10: 193-204
88. Peiris AN, Mueller RA, Struve MF, et al. Relationship of androgenic activity to splanchnic insulin metabolism and peripheral glucose utilization in premenopausal women. J Clin Endocrinol Metab 1987; 64: 162-9
89. Farah MJ, Givens JR, Kitabchi AE. Bimodal correlation between the circulating insulin level and the production rate of dehydroepiandrosterone: positive correlation in controls and negative correlation in the polycystic ovary syndrome with acanthosis nigricans. J Clin Endocrinol Metab 1990; 70: 1075-81
90. Nestler JE, Clore JN, Strauss III JF, et al. The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and Cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans. J Clin Endocrinol Metab 1987; 64: 180-4
91. Falcone T, Finegood DT, Fantus IG, et al. Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women. J Clin Endocrinol Metab 1990; 71: 1653-7
92. Nestler JE, Beer NA, Jakubowicz DJ, et al. Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab 1994; 78: 549-54
93. Hubert GD, Schriock ED, Givens JR, et al. Suppression of circulating androstenedione and dehydroepiandrosterone sulfate during oral glucose tolerance lest in normal females. J Clin Endocrinol Metab 1991; 73: 781-4
94. Diamond MP, Grainger DA, Laudano AJ, et al. Effect of acute physiological elevations of insulin on circulating androgen levels in nonobese women. J Clin Endocrinol Metab 1991; 72: 883-7
95. Remer T, Pietzik K. Chronic insulin treatment, but not chronic ACTH administration, increases plasma dehydroepiandrosterone sulfate levels in adolescent male rats. Exp Clin Endocrinol 1993; 101: 222-9
96. Nestler JE, McClanahan MA, Clore JN, et al. Insulin inhibits adrenal 17,20-lyase activity in man. J Clin Endocrinol Mclab 1992; 74: 362-7
97. Liu CH, Laughlin GA, Yen SS. Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17,20-desmolase enzymatic activity. J Clin Endocrinol Metab 1990; 71: 900-6
98. Nestler JE, Usiskin KS, Barlascini CO, et al. Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. J Clin Endocrinol Metab 1989; 69: 1040-6
99. Mortola JF, Yen SSC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in post-menopausal women. J Clin Endocrinol Metab 1990; 71: 646-704
100. Usiskin KS, Butterworth S, Clore JN, et al. Lack of effect of dehydroepiandrosterone in obese men. Int J Obes 1990; 14: 457-63
101. Welle S, Jozefowicz R, Statt M. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J Clin Endocrinol Metab 1990; 71: 1259-64
102. Nestler JE, Barlascini CO, Clore JN, et al. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988; 66: 57-61
103. Porter JR, Svec F. DHEA diminishes fat food intake in lean and obese Zucker rats. Ann N Y Acad Sci 1995; 774: 329-31
104. Buffington CK, Givens JR, Kitabchi AE. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity: in vivo and in vitro studies of hyperandrogenic females. Diabetes 1991; 40: 693-700
105. Bates Jr GW, Egerman RS, Umstot ES, et al. Dehydroepiandrosterone attenuates study-induced declines in insulin sensitivity in postmenopausal women. Ann N Y Acad Sci 1995; 774: 291-3
106. Haffner SM, Valdez RA, Stern MP, et al. Obesity, body fat distribution and sex hormones in men. Int J Obes 1993; 17: 643-9
107. Buffington CK, Pourmotabbed G, Kitabchi AE. Case report: amelioration of insulin resistance in diabetes with dehydroepiandrosterone. Am J Med Sci 1993; 306: 320-4
108. Schriock ED, Buffington CK, Hubert GD, et al. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab 1988; 66: 1259-331
109. Haffner SM, Valdez RA, Mykkanen L, et al. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994; 43: 599-603
110. Haffner SM, Karhapaa P, Mykkanen L, et al. Insulin resistance, body fat distribution and sex hormones in men. Diabetes 1994; 43: 212-4
111. Bates Jr GW, Egerman RS, Umstot KS, et al. Dehydroepiandrosterone attenuates study-induced declines in insulin sensitivity in postmenopausal women. Ann N Y Acad Sci 1995; 774: 291-3
112. Bush TL, Barrot CH. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 1985; 7: 80-104
113. Eaker ED, Packard B, Thom TJ. Epidemiology and risk factors for coronary heart disease in women. Cardiovasc Clin 1988; 19: 129-45
114. Wang DY, Hayword JL, Bulbrook RD, et al. Plasma DHEA and androsterone sulphates and androstenedione and urinary androgen metabolites in normal British and Japanese women. Eur J Cancer 1976; 12: 951-8
115. Wang DY, Bulbrook RD, Clifford P, et al. Plasma level of the sulphate esters of DHEA and androsterone in Kenyan men and their relation to cancer of the nasopharynx. Lancet 1968; 1: 1003-4
116. Gordon GB, Shantz LM, Talalay P. Modulation of growth, differentiation and carcinogenesis by DHEA. Adv Enzyme Regul 1987; 26: 355-82
117. Saenger P, New M. Inhibitory action of DHEA on fibroblast growth. Experientia 1977; 33: 966-7
118. Lopez SA, Krehli WA. A possible interrelation between glucose-6-phosphate dehydrogenase and DHEA in obesity. Lancet 1967; 11: 485-7
119. Lopez SA, Krehli WA. In vivo effect of DHEA on red blood cell glucose-6-phosphate dehydrogenase. Proc Soc Exp Biol Med 1967; 126: 776-8
120. Herrington DM, Gordon GB, Achuff SC, et al. Plasma DHEA and DHEA-S in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 1990; 16: 862-70
121. Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement doses of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360-7
122. Williams DP, Boyden TW, Pamenter RW, et al. Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premenopausal females. J Clin Endocrinol Metab 1993; 77: 80-5
123. Gordon GB, Bush DE, Wiesman HF. Reduction of atherosclerosis by administration of DHEA. J Clin Invest 1988; 82: 712-20
124. Mitchell LE, Spreacher DL, Borecki IB, et al. Evidence for an association between dehydroepiandrosterone sulfate and non-fatal, premature myocardial infarction in males. Circulation 1994; 89: 89-93
125. Ishihara F, Hiramatsu K, Shigematsu S, et al. Role of adrenal androgens in the development of atherosclerosis as judged by pulse wave velocity and calcification of the aorta. Cardiology 1992; 80: 332-8
126. LaCroiz AZ, Yano K, Reed DM. Dehydroepiandrosterone sulfate, incidence of myocardial infarction and extent of atherosclerosis in men. Circulation 1992; 86: 1529-35
127. Contoreggi CS, Blackman MR, Andres R, et al. Plasma levels of estradiol, testosterone and DHEAS do not predict risk of coronary artery disease in men. J Androl 1990; 11: 460-70
128. Rice T, Sprecher DL, Borecki IB, et al. The Cincinnati Myocardial Infarction and Hormone Family Study: family resemblance for dehydroepiandrosterone sulfate in control and myocardial infarction families. Metabolism 1993; 42: 1284-90
129. Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. Ann N Y Acad Sci 1995; 774: 259-70
130. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Ann N Y Acad Sci 1995; 774: 271-80
131. Jesse RL, Loesser K, Eich DM, et al. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann N Y Acad Sci 1995; 774: 281-90
132. Hautanen A, Manttari M, Manninen V, et al. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 1994; 105: 191-200
133. Sanka J, Fassati M, Fassati P, et al. Serum lipids and DHEA secretion in normal subjects. J Lipid Res 1968; 9: 769-72
134. Lopez SA, Wingo C, Herbert JA. Total serum cholesterol and urinary DHEA in humans. Atherosclerosis 1976; 24: 471-81
135. Aldercreutz H, Kerstell J, Schaumann KO, et al. Plasma lipids and steroid hormones in patients with hypercholesterolemia or hyperlipidemia during DHEA-S administration. Eur J Clin Invest 1972; 2: 91-5
136. Philip T, Srivatava GN, Pratap S. Diagnostic characters of topical Dioscoreas: pharmacognostic study of some common Indian Discoreas part 1. Q J Crude Drug Res 1980; 18: 169-84
137. Bergner P. Wild yam and hormonal synthesis [letter]. Med Herbalism 1992; 4: 4
138. Rosenkranz G, Djerssi C, Yashin C, et al. Cortical hormones from allosteroids: synthesis of cortisone from reichestein compound. Nature 1951; 168: 28-35
139. Mirkin G. Estrogen in yams. JAMA 1991; 265: 912
140. Araghinikuam M, Chung S, Nelson-White T, et al. Antioxidant activity of Dioscorea and dehydroepiandrosterone (DHEA) in older humans. Life Sci. In press
141. Herbert J. The age of dehydroepiandrosterone. Lancet 1995; 345: 1193-5